Insider Trading Activity Syros Pharmaceuticals Inc – Director Bought 109,774 shares of Stock

ME Staff
-
0

Insider Trading Activity For Syros Pharmaceuticals Inc

Srinivas Akkaraju , Director of Syros Pharmaceuticals Inc reportedly Bought 109,774 shares of the company’s stock at an average price of 9.03 for a total transaction amount of $991,259.22 SEC Form

Insider Trading History For Syros Pharmaceuticals Inc

  • On 7/6/2016 Robert Nelsen, Director, bought 400,000 with an average share price of $12.50 per share and the total transaction amounting to $5,000,000.00.View SEC Filing
  • On 7/6/2016 Redmile Group, Llc, Major Shareholder, bought 432,746 with an average share price of $12.50 per share and the total transaction amounting to $5,409,325.00.View SEC Filing
  • On 7/25/2017 Richard A Young, Director, sold 3,282 with an average share price of $22.09 per share and the total transaction amounting to $72,499.38.View SEC Filing
  • On 7/25/2017 Eric R Olson, Insider, sold 12,500 with an average share price of $21.85 per share and the total transaction amounting to $273,125.00.View SEC Filing
  • On 8/7/2017 Eric R Olson, Insider, sold 2,500 with an average share price of $23.59 per share and the total transaction amounting to $58,975.00.View SEC Filing
  • On 8/14/2017 Richard A Young, Director, sold 3,282 with an average share price of $22.00 per share and the total transaction amounting to $72,204.00.View SEC Filing
  • On 10/23/2017 Colleen Elizabeth Desimone, Insider, sold 550 with an average share price of $16.06 per share and the total transaction amounting to $8,833.00.View SEC Filing

    • Analyst Ratings History For Syros Pharmaceuticals Inc

    • On 9/9/2016 HC Wainwright Reiterated Rating Hold with a price target of $10.00
    • On 8/10/2017 Wedbush Reiterated Rating Outperform with a price target of $25.00 to $22.84
    • On 8/21/2017 Cann Reiterated Rating Buy with a price target of $28.00
    • On 9/28/2017 JMP Securities Upgraded rating Market Perform to Outperform with a price target of $33.00
    • On 10/23/2017 Roth Capital Initiated Coverage of rating Neutral to Neutral with a price target of $15.00
    • On 10/31/2017 Piper Jaffray Companies Reiterated Rating Overweight to Overweight with a price target of $30.00
    • On 12/11/2017 Cowen Reiterated Rating Buy

    Recent Trading Activity for Syros Pharmaceuticals Inc
    Shares of Syros Pharmaceuticals Inc closed the previous trading session at with shares trading hands.